Search results for "243"

showing 10 items of 43 documents

beta-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in beta 2-Adrenoceptor Knockout Mice

2016

Background and Objective. In order to characterize the β-adrenoceptor (AR) subtypes involved in agonist-stimulated relaxation of murine urinary bladder we studied the effects of (-)-isoprenaline and CL 316,243 on tonic contraction and spontaneous contractions in detrusor strips of wild-type (WT) and β2-AR knockout (β2-AR KO) mice. Materials and Methods. Urinary bladders were isolated from male WT and β2-AR KO mice. β-AR subtype expression was determined with quantitative real-time PCR. Intact muscle strips pre-contracted with KCl (40 mM) were exposed to cumulatively increasing concentrations of (-)-isoprenaline or β3-AR agonist CL 316,243 in the presence and absence of the subtype-selective…

0301 basic medicineDetrusor muscleAgonistmedicine.medical_specialtyAdrenergic receptormedicine.drug_class030232 urology & nephrology03 medical and health sciences0302 clinical medicinerelaxationInternal medicineIsoprenalinemedicinePotencyPharmacology (medical)ddc:610ReceptorCL 316243mucosaOriginal ResearchPharmacologyisoprenalineUrinary bladderChemistryβ3-adrenoceptorsdetrusor muscle030104 developmental biologymedicine.anatomical_structureEndocrinologyKnockout mouseβ2-adrenoceptor knockoutmedicine.drug
researchProduct

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity

2021

BackgroundTumor microenvironment-associated T cell senescence is a key limiting factor for durable effective cancer immunotherapy. A few studies have demonstrated the critical role of the tumor suppressor TP53-derived p53 isoforms in cellular senescence process of non-immune cells. However, their role in lymphocytes, in particular tumor-antigen (TA) specific T cells remain largely unexplored.MethodsHuman T cells from peripheral blood were retrovirally engineered to coexpress a TA-specific T cell receptor and the Δ133p53α-isoform, and characterized for their cellular phenotype, metabolic profile and effector functions.ResultsPhenotypic analysis of Δ133p53α-modified T cells revealed a marked …

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentT cellT-LymphocytesImmunologyReceptors Antigen T-Cell2436receptorsBiologycell engineeringadoptive03 medical and health sciencesMice0302 clinical medicineantigenTIGITCancer immunotherapyAntigenCell Line TumorNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumans1506RC254-282PharmacologyImmune Cell Therapies and Immune Cell EngineeringCD28Neoplasms. Tumors. Oncology. Including cancer and carcinogensT lymphocyteImmunotherapycostimulatory and inhibitory T-cell receptorsCell biology030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisMolecular MedicineimmunotherapyCD8Journal for ImmunoTherapy of Cancer
researchProduct

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer

2021

BackgroundThe prognosis of early breast cancer is linked to clinic-pathological stage and the molecular characteristics of intrinsic tumor cells. In some patients, the amount and quality of tumor-infiltrating immune cells appear to affect long term outcome. We aimed to propose a new tool to estimate immune infiltrate, and link these factors to patient prognosis according to breast cancer molecular subtypes.MethodsWe performed in silico analyses in more than 2800 early breast cancer transcriptomes with corresponding clinical annotations. We first developed a new gene expression deconvolution algorithm that accurately estimates the quantity of immune cell populations (tumor immune contexture,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMyeloid2435In silicoImmunologyCellbiostatisticsBreast NeoplasmsTranscriptome03 medical and health sciences0302 clinical medicineBreast cancerImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorImmunology and Allergytumor microenvironmentHumans1506Stage (cooking)RC254-282Neoplasm StagingPharmacologyClinical/Translational Cancer ImmunotherapyTumor microenvironmentbusiness.industryGene Expression ProfilingNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosisSurvival AnalysisGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesistumor biomarkersMolecular MedicineFemalebusinessAlgorithmsUnsupervised Machine LearningJournal for Immunotherapy of Cancer
researchProduct

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCO…

2020

BackgroundSkin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concomitant diseases. Due to their previous exclusion from clinical trials, the ICI treatment efficacy is poorly investigated in these patients. The present study analyzed the ICI treatment outcome in advanced patients with skin cancer with a concomitant hematological malignancy.MethodsThis retrospective multicenter study included patients who were treated with ICI for locally advanced or metastatic melanoma (MM), cutaneous squamous cell carcinoma (cS…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtySkin Neoplasms2435medicine.medical_treatmentChronic lymphocytic leukemiaImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicinemelanomaImmunology and AllergyHumans1506Immune Checkpoint InhibitorsRC254-282AgedRetrospective StudiesPharmacologyClinical/Translational Cancer ImmunotherapyMerkel cell carcinomabusiness.industryMelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapyMiddle Agedmedicine.diseaseSurvival AnalysisLymphoma030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantHematologic NeoplasmsMolecular MedicineFemaleImmunotherapySkin cancerbusinessProgressive diseaseJournal for Immunotherapy of Cancer
researchProduct

“El Registro Civil y el contenido de su publicidad: experiencias españolas para el contexto cubano”

2021

La función de publicidad que caracteriza al Registro Civil lo convierte en una institución fundamental dentro del sistema de seguridad jurídica preventiva. De ahí que, sea importante estudiar si existe correspondencia entre el contenido de la publicidad del Registro y las situaciones jurídicas y sociales en que usualmente se desenvuelven las personas, como un medio para garantizar, desde esta perspectiva, su cuidado y desarrollo. En este sentido, se valora el contenido de la publicidad del Registro del Estado Civil cubano (Ley No.51/1985, de 15 de julio del Registro del Estado Civil), a partir de las experiencias españolas en la materia, siguiendo, en general, los avances de este último sis…

:CIENCIAS JURÍDICAS [UNESCO]Malena La función de publicidad que caracteriza al Registro Civil lo convierte en una institución fundamental dentro del sistema de seguridad jurídica preventiva. De ahí queen general2070-8157 22082 Revista Boliviana de Derecho 584568 2021 32 8055243 El Registro Civil y el contenido de su publicidad experiencias españolas para el contexto cubano Proenza Reyessea importante estudiar si existe correspondencia entre el contenido de la publicidad del Registro y las situaciones jurídicas y sociales en que usualmente se desenvuelven las personasRegistro Civilcomo un medio para garantizarse valora el contenido de la publicidad del Registro del Estado Civil cubano (Ley No.51/1985de 21 de julioEspañaCubade 15 de julio del Registro del Estado Civil)y la necesidad de alcanzar en el ámbito registral cubano mayor protección a la persona y la familia. Contenido de publicidadlos avances de este último sistema (Ley 20/2011Publicity contentsu cuidado y desarrollo. En este sentidoSpain 934 965UNESCO::CIENCIAS JURÍDICASa partir de las experiencias españolas en la materiaCivil Registrydesde esta perspectivasiguiendodel Registro Civil)
researchProduct

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of…

2020

BackgroundImmune checkpoint inhibition (ICI) is an essential treatment option in melanoma. Its outcome may be improved by a preceding radiation of metastases. This study aimed to investigate the impact of a preceding radiotherapy on the clinical outcome of ICI treatment.MethodsThis multicenter retrospective cohort study included patients who received anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or anti-programmed cell death protein 1 (PD-1) ICI with or without preceding radiotherapy for unresectable metastatic melanoma. ICI therapy outcome was measured as best overall response (BOR), progression-free (PFS) and overall survival (OS). Response and survival analyses were adjusted …

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtySkin NeoplasmsMetastatic melanoma2435medicine.medical_treatmentProgrammed Cell Death 1 ReceptorImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyCTLA-4 Antigen1506Immune Checkpoint InhibitorsMelanomaradiotherapyRC254-282Survival analysisRetrospective StudiesClinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryMelanomaConfoundingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyChemoradiotherapyMiddle Agedmedicine.diseaseProgression-Free SurvivalImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMolecular MedicineFemalebusinessJournal for ImmunoTherapy of Cancer
researchProduct

Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome

2021

BackgroundBreast cancer (BC) progression to metastatic disease is the leading cause of death in women worldwide. Metastasis is driven by cancer stem cells (CSCs) and signals from their microenvironment. Interleukin (IL) 30 promotes BC progression, and its expression correlates with disease recurrence and mortality. Whether it acts by regulating BCSCs is unknown and could have significant therapeutic implications.MethodsHuman (h) and murine (m) BCSCs were tested for their production of and response to IL30 by using flow cytometry, confocal microscopy, proliferation and sphere-formation assays, and PCR array. Immunocompetent mice were used to investigate the role of BCSC-derived IL30 on tumor…

Cancer Research2434ImmunologyTriple Negative Breast NeoplasmsBiologyInterleukin-23Paracrine signallingMiceCancer stem cellCell Line Tumorbreast neoplasmsImmunology and Allergytumor microenvironmentAnimalsHumans1506Autocrine signallingRC254-282PharmacologyTumor microenvironmentbreast neoplasms cytokines tumor microenvironmentInterleukinsInnate lymphoid cellNeoplasms. Tumors. Oncology. Including cancer and carcinogensFOXP3Basic Tumor ImmunologyDendritic cellcytokinesChemokine CXCL10Autocrine CommunicationOncologyKLF4Cancer researchNeoplastic Stem CellsMolecular MedicineFemaleJournal for Immunotherapy of Cancer
researchProduct

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

2020

BackgroundWe have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.MethodsThis randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS.ResultsAt a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 mont…

Cancer Researchmedicine.medical_specialty2435[SDV]Life Sciences [q-bio]ImmunologyMedizinIpilimumabrandomized trialsGastroenterologyAsymptomaticlaw.inventionimmunology03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineClinical endpointImmunology and Allergy1506030212 general & internal medicineAdverse effectRC254-282Clinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryIncidence (epidemiology)MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseimmunology; oncology; randomized trials[SDV] Life Sciences [q-bio]Oncology030220 oncology & carcinogenesisoncologyMolecular Medicinemedicine.symptombusinessBrain metastasismedicine.drug
researchProduct

Interacciones dieta-genotipo entre el consumo de grasas y polimorfismos comunes determinando el metabolismo lipídico

2009

Las recomendaciones dietéticas actuales referentes al consumo de grasas en la dieta han sido realizadas sin tener en cuenta las posibles diferencias genéticas de las personas que podrían ser las responsables de las diferentes respuestas interindividuales que frecuentemente se observan ante la misma dieta. La presencia de variabilidad genética ha sido puesta de manifiesto para todos los genes relacionados con el metabolismo lipídico, por lo que existe un ingente número de genes y de variantes genéticas para ser incluidas en los estudios sobre interacciones dieta-genotipo en el ámbito específico del consumo de grasas y aceites. Se revisarán algunos ejemplos sobre interacciones grasa-genotipo.…

Candidate genemedicine.medical_specialtyInteractionPopulationNutrigenéticalcsh:TX341-641BiologyDieta; Genes; Interacción; Lípidos; Nutrigenética; PolimorfismosLípidosNutrigeneticsInteracciónNutrigenéticaInternal medicineAPOA1 GenemedicineTX341-641PPARA GeneGenetic variabilityeducationNutrigeneticsGeneticseducation.field_of_studyNutrition. Foods and food supplyOrganic ChemistryPolimorfismosLipid metabolism:CIENCIAS MÉDICAS [UNESCO]LipidsDietEndocrinologyNutrigenomicsGenesInteracciónUNESCO::CIENCIAS MÉDICASLípidoslipids (amino acids peptides and proteins)DietaPolymorphismslcsh:Nutrition. Foods and food supplyFood Science
researchProduct

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

2021

BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a poor cure rate for relapsed/resistant patients. Due to the lack of T-cell restricted targetable antigens, effective immune-therapeutics are not presently available and the treatment of chemo-refractory T-ALL is still an unmet clinical need. To develop novel immune-therapy for T-ALL, we generated an afucosylated monoclonal antibody (mAb) (ahuUMG1) and two different bispecific T-cell engagers (BTCEs) against UMG1, a unique CD43-epitope highly and selectively expressed by T-ALL cells from pediatric and adult patients.MethodsUMG1 expression was assessed by immunohistochemistry (IHC) on a wide panel of normal t…

Cytotoxicity ImmunologicCancer Research2434T-LymphocytesMice SCIDafucosylated monoclonal antibodyLymphocyte ActivationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaEpitopesJurkat CellsAntineoplastic Agents ImmunologicalAntibody SpecificityMice Inbred NODantigensAntibodies BispecificTumor MicroenvironmentImmunology and Allergyantibodieshematologic neoplasms1506RC254-282Antibody-dependent cell-mediated cytotoxicityLeukosialinbispecific T-cell engagersmedicine.diagnostic_testbiologyhematological malignancieNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureantibodieOncologytranslational medical researchMolecular MedicineImmunohistochemistryFemaleimmunotherapyAntibodyT-ALLT-cell engagersT-cell acute lymphoblastic leukemiamedicine.drug_classT cellImmunologySettore MED/08 - Anatomia PatologicaMonoclonal antibodyAntibodies Monoclonal HumanizedFlow cytometryT Acute Lymphoblastic LeukemiaantigenAntigenPhagocytosismedicineAnimalsHumanshematological malignanciesCell ProliferationPharmacologyT-cell engagerbusiness.industryhematological malignancies; antibodies; antigens; hematologic neoplasms; immunotherapy; neoplasm; T-ALL; T-cell engagers; translational medical research; translational researchBasic Tumor ImmunologyXenograft Model Antitumor Assaystranslational researchCancer researchbiology.proteinneoplasmbusinesshematologic neoplasmneoplasm
researchProduct